Press Releases

06.05.2016

Weizmann Institute of Science Announces Visiting Scientist Agreement with Pfizer Inc.

06.04.2016

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

05.31.2016

BioRap Technologies to enter strategic collaboration with Pfizer Inc. to research and develop novel immunomodulators

05.23.2016

CHAMPIX® (varenicline) European Union Label Updated to Include New Safety and Efficacy Data from the EAGLES Clinical Trial Following Endorsement from CHMP

05.20.2016

Pfizer Announces European Medicines Agency Acceptance for Review of Marketing Authorization Application for TRUMENBA® (Meningococcal Group B Vaccine)

05.19.2016

Spark Therapeutics and Pfizer Announce Data from Initial Subjects in Hemophilia B Trial Demonstrating Consistent Therapeutic Levels of Factor IX Expression

05.18.2016

Merck KGaA, Darmstadt, Germany, and Pfizer to Present Avelumab Data in Seven Different Cancers at ASCO Annual Meeting

05.18.2016

Pfizer to Showcase Diverse and Growing Oncology Portfolio at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting

05.17.2016

Global Survey Finds Disconnects Between Physicians and People Living With Rheumatoid Arthritis (RA)

05.16.2016

Pfizer to Acquire Anacor

05.13.2016

Pfizer Presents Results from Two Phase 3 TRUMENBA® (Meningococcal Group B Vaccine) Studies at the European Society for Paediatric Infectious Diseases Meeting

05.11.2016

Pfizer Awards More Than $1 Million in Metastatic Breast Cancer Research Funding Through Breast Cancer: A Story Half Told Initiative